| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $6.1M | -1.7% | +18.6% |
| SG&A Expense | $4.5M | -2.3% | +3.0% |
| Operating Income | -$7.2M | +34.4% | +27.5% |
| Net Income | -$7.6M | +32.2% | +15.5% |
| EPS (Basic) | -$1.07 | +37.4% | +44.6% |
| EPS (Diluted) | -$1.07 | +37.4% | +44.6% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $21.1M | -34.0% | -57.1% |
| Current Assets | $24.3M | -27.9% | -52.7% |
| Total Assets | $25.0M | -30.6% | -53.7% |
| Current Liabilities | $32.6M | +103.4% | +36.5% |
| Long-term Debt | $26.9M | +0.0% | -20.6% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$27.4M | -65.7% | — |
| Investing Cash Flow | -$15K | — | — |
| Financing Cash Flow | -$2.6M | — | — |
| $33.7M |
| -14.2% |
| -28.7% |
| Stockholders' Equity | -$8.7M | -170.3% | -226.3% |